Search International and National Patent Collections

1. (WO2018137294) TRANSGENIC LYMPHOCYTE CO-EXPRESSING ANTI-MSLN CHIMERIC ANTIGEN RECEPTOR AND NON-FUNCTIONAL EGFR AND USE THEREOF

Pub. No.:    WO/2018/137294    International Application No.:    PCT/CN2017/081273
Publication Date: Fri Aug 03 01:59:59 CEST 2018 International Filing Date: Fri Apr 21 01:59:59 CEST 2017
IPC: C12N 5/10
C12N 7/01
C12N 15/867
C12N 15/864
A61K 35/17
A61P 35/00
Applicants: BEIJING MARINO BIOTECHNOLOGY PTY LTD.
北京马力喏生物科技有限公司
Inventors: YAN, Yongchao
严勇朝
ZHU, Yilin
朱益林
CHEN, Siyi
陈思毅
Title: TRANSGENIC LYMPHOCYTE CO-EXPRESSING ANTI-MSLN CHIMERIC ANTIGEN RECEPTOR AND NON-FUNCTIONAL EGFR AND USE THEREOF
Abstract:
Provided are a transgenic lymphocyte, a construct, and a therapeutic composition for treating a cancer. The transgenic lymphocyte expresses a non-functional EGFR and a chimeric antigen receptor. The chimeric antigen receptor comprises an extracellular domain, and the extracellular domain comprises a heavy chain variable region and a light chain variable region of a single-chain antibody. The single-chain antibody specifically recognizes an antigen, MSLN. The chimeric antigen receptor further comprises a transmembrane domain. The transmembrane domain is connected with the extracellular domain and is embedded in the membrane of the lymphocyte. The chimeric antigen receptor further comprises an intracellular domain. The intracellular domain is connected with the transmembrane domain and comprises an intracellular segment of CD28 or 4-1BB and a CD3ζ chain.